Life Technologies Announces Regulatory Approval of 3500 Dx Series Genetic Analyzers in Mexico
Share:
CARLSBAD, Calif. – Life Technologies Corporation (NASDAQ: LIFE) today announced that its Applied Biosystems™ 3500 Dx and 3500xL Dx Genetic Analyzers have been approved by the Federal Commission for Protection against Health Risks in Mexico for diagnostic use. The development marks a major extension of Life Technologies' capabilities to serve the clinical end market in North America with Sanger-based solutions.Â
The Applied Biosystems™ 3500 Dx Series Genetic Analyzers deliver high quality performance, higher throughput and increased productivity for clinical laboratories around the world. The 3500xL Dx is an automated 24 capillary-based Sanger Sequencer; the 3500 Dx is an eight capillary instrument. Together, the offering of both 3500 Dx and 3500xL Dx provides hospitals of all sizes the flexibility they need to meet their unique throughput demands designed for a wide range of sequencing applications. In addition to diagnostic use, the instruments are appropriate for a wide range of research applications, including de novo sequencing and mutational profiling.Â
"The current approval of the 3500 Dx Series Genetic Analyzers emphasizes Life Technologies' success in pursuing regulatory pathways for our diagnostics laboratory instruments, as well as our vision to becoming a global leader in the molecular diagnostics industry," said Ronnie Andrews, president of Medical Sciences at Life Technologies.
Applied Biosystems Sanger Sequencers supplied the technology that powered the Human Genome Project, and Sanger instruments remain the sequencing "gold-standard" for accuracy, reliability and ease of use. The participation of the sequencing technologies in clinical diagnostics is reshaping the disease treatment paradigm worldwide.    Â
Additional products offered by Life Technologies for the molecular diagnostics lab market in Mexico include the Applied Biosystems 7500 Fast Dx Real-time PCR instrument, approved for diagnostic use by the Federal Commission for Protection against Health Risks in Mexico in January, 2013.
About Life Technologies
Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology company that is committed to providing the most innovative products and services to leading customers in the fields of scientific research, genetic analysis and applied sciences. With a presence in more than 180 countries, the company's portfolio of 50,000 end-to-end solutions is secured by more than 5,000 patents and licenses that span the entire biological spectrum - scientific exploration, molecular diagnostics, 21st century forensics, regenerative medicine and agricultural research. Life Technologies has approximately 10,000 employees and had sales of $3.8 billion in 2012.
Life Technologies Contact
Suzanne Clancy
760-602-4545
858-205-4235 (mobile)
suzanne.clancy@lifetech.com
SOURCEÂ
Life Technologies Corporation
